Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine

References

• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20(10):2429–2440.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer. 2011;117(12):2697–2702.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the Alternative Dosing for Outpatient Treatment (ADOPT) trial. J Clin Oncol. 2009;27(23):3842–3848.
   PubMed Web of Science ®Google Scholar
• Santini V. Advances in myelodysplastic syndrome. Curr Opin Oncol. 2021;33(6):681–686.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–2677.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299.
   PubMed Web of Science ®Google Scholar
• Pleyer L, Dohner H, Dombret H, et al. Azacitidine for front-line therapy of patients with AML: reproducible efficacy established by direct comparison of international phase 3 trial data with registry data from the Austrian azacitidine registry of the AGMT study group. Int J Mol Sci. 2017;18(2):415.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein AS, Stein EM, et al. Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia. J Clin Oncol. 2021;39(1):57–65.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
   PubMed Web of Science ®Google Scholar
• Stomper J, Rotondo JC, Greve G, et al. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021;35(7):1873–1889.
   PubMed Web of Science ®Google Scholar
• Wang R, Gross CP, Frick K, et al. The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leuk Res. 2012;36(11):1370–1375.
   PubMed Web of Science ®Google Scholar
• Guirguis HR, Charbonneau LF, Tyono I, et al. Shelf-life extension of azacitidine: waste and cost reduction in the treatment of myelodysplastic syndromes. Leuk Lymphoma. 2015;56(2):542–544.
   PubMed Web of Science ®Google Scholar
• Kipp D, Wei AH. The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes. Future Oncol. 2021;17(20):2563–2571.
   PubMed Web of Science ®Google Scholar
• Inqovi FDA; 2021. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-oral-combination-decitabine-and-cedazuridine-myelodysplastic-syndromes
   Google Scholar
• Onureg FDA; 2021. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-onureg-azacitidine-tablets-acute-myeloid-leukemia
   Google Scholar
• Mund C, Hackanson B, Stresemann C, et al. Characterization of DNA demethylation effects induced by 5-Aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res. 2005;65(16):7086–7090.
   PubMed Web of Science ®Google Scholar
• Yang AS, Doshi KD, Choi SW, et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res. 2006;66(10):5495–5503.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009;114(16):3448–3458.
   PubMed Web of Science ®Google Scholar
• Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood. 2002;100(8):2957–2964.
   PubMed Web of Science ®Google Scholar
• Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123(1):8–13.
   PubMed Web of Science ®Google Scholar
• Navada SC, Steinmann J, Lubbert M, et al. Clinical development of demethylating agents in hematology. J Clin Invest. 2014;124(1):40–46.
   PubMed Web of Science ®Google Scholar
• Santi DV, Garrett CE, Barr PJ. On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell. 1983;33(1):9–10.
   PubMed Web of Science ®Google Scholar
• Li LH, Olin EJ, Buskirk HH, et al. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res. 1970;30(11):2760–2769.
   PubMed Web of Science ®Google Scholar
• Li LH, Olin EJ, Fraser TJ, et al. Phase specificity of 5-azacytidine against mammalian cells in tissue culture. Cancer Res. 1970;30(11):2770–2775.
   PubMed Web of Science ®Google Scholar
• Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother. 2014;5(3):186–192.
   PubMedGoogle Scholar
• Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103(5):1635–1640.
   PubMed Web of Science ®Google Scholar
• Raza A, Assal A, Ali AM, et al. Rewriting the rules for care of MDS and AML patients in the time of COVID-19. Leuk Res Rep. 2020;13:100201.
   PubMedGoogle Scholar
• Greenberg PL, Stone RM, Al-Kali A, et al. Myelodysplastic syndromes, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(1):60–87.
   PubMed Web of Science ®Google Scholar
• Pan F, Peng S, Fleurence R, et al. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US Payer Perspective. Clin Ther. 2010;32(14):2444–2456.
   PubMed Web of Science ®Google Scholar
• Ma X. Epidemiology of myelodysplastic syndromes. Am J Med. 2012;125(7 Suppl.):S2–S5.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Wang R, Davidoff A, et al. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70–87.
   PubMed Web of Science ®Google Scholar
• Finn L, Sproat L, Heckman MG, et al. Epidemiology of adult acute myeloid leukemia: impact of exposures on clinical phenotypes and outcomes after therapy. Cancer Epidemiol. 2015;39(6):1084–1092.
   PubMed Web of Science ®Google Scholar
• Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–1117.
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299–1307.
   PubMed Web of Science ®Google Scholar
• Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59(1):56–66.
   PubMed Web of Science ®Google Scholar
• Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401–5411.
   PubMed Web of Science ®Google Scholar
• Ousseine YM, Butow PN, Fenaux P, et al. Association between health literacy, communication and psychological distress among myelodysplastic syndromes patients. Leuk Res. 2018;73:44–50.
   PubMed Web of Science ®Google Scholar
• Voso MT, Santini V, Fabiani E, et al. Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica. 2014;99(4):613–619.
   PubMed Web of Science ®Google Scholar
• Babiker HM, Milhem M, Aisner J, et al. Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer Chemother Pharmacol. 2020;85(3):621–626.
   PubMed Web of Science ®Google Scholar
• Laille E, Savona MR, Scott BL, et al. Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. J Clin Pharmacol. 2014;54(6):630–639.
   PubMed Web of Science ®Google Scholar
• Forsythe A, Sandman K. What does the economic burden of acute myeloid leukemia treatment look like for the next decade? An analysis of key findings, challenges and recommendations. J Blood Med. 2021;12:245–255.
   PubMed Web of Science ®Google Scholar
• Ward MR, Stoltz ML, Etter JB, et al. An oral dosage formulation of azacitidine: a pilot pharmacokinetic study. J Clin Oncol. 2007;25(18 Suppl.):7084.
   Web of Science ®Google Scholar
• Garcia-Manero G, Stoltz ML, Ward MR, et al. A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008;22(9):1680–1684.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011;29(18):2521–2527.
   PubMed Web of Science ®Google Scholar
• Laille E, Shi T, Garcia-Manero G, et al. Pharmacokinetics and pharmacodynamics with extended dosing of CC-486 in patients with hematologic malignancies. PLOS One. 2015;10(8):e0135520.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Gore SD, Kambhampati S, et al. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016;30(4):889–896.
   PubMed Web of Science ®Google Scholar
• Savona MR, Kolibaba K, Conkling P, et al. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. Am J Hematol. 2018;93(10):1199–1206.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Scott BL, Cogle CR, et al. CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. Leuk Res. 2018;72:79–85.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Almeida A, Giagounidis A, et al. Design and rationale of the QUAZAR lower-risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia. BMC Hematol. 2016;16(1):12.
   PubMedGoogle Scholar
• Garcia-Manero G, Santini V, Almeida A, et al. Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2021;39(13):1426–1436.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Montesinos P, Selleslag D, et al. Design of the randomized, phase III, QUAZAR AML maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncol. 2016;12(3):293–302.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Bixby D, Perl A, et al. Acute myeloid leukemia, version 2.2021 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2021;19(1):17–27.
   Web of Science ®Google Scholar
• Wei AH, Dohner H, Pocock C, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383(26):2526–2537.
   PubMed Web of Science ®Google Scholar
• Wei AH, Dohner H, Pocock C, et al. The QUAZAR AML-001 maintenance trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission. Blood. 2019;134(Suppl. 2):LBA-3.
   Google Scholar
• Ravandi F, Roboz GJ, Wei AH, et al. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. J Hematol Oncol. 2021;14(1):133.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Dohner H, Pocock C, et al. Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. Haematologica. 2021;106(12):3240–3244.
   PubMed Web of Science ®Google Scholar
• Dohner H, Wei AH, Roboz GJ, et al. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Blood. 2022;140(15):1674–1685.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Ravandi F, Wei AH, et al. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. Blood. 2022;139(14):2145–2155.
   PubMed Web of Science ®Google Scholar
• Hassanein M, Atenafu EG, Schuh AC, et al. High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission. Leuk Res. 2013;37(5):556–560.
   PubMed Web of Science ®Google Scholar
• Cherry EM, Abbott D, Amaya M, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021;5(24):5565–5573.
   PubMed Web of Science ®Google Scholar
• Schroeder T, Frobel J, Cadeddu RP, et al. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. Leukemia. 2013;27(9):1910–1913.
   PubMed Web of Science ®Google Scholar
• de Lima M, Oran B, Champlin RE, et al. CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes. Biol Blood Marrow Transplant. 2018;24(10):2017–2024.
   PubMed Web of Science ®Google Scholar
• El Chaer F, Borate U, Dulery R, et al. Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML. Blood Adv. 2021;5(6):1757–1759.
   PubMed Web of Science ®Google Scholar
• Mesia R, Bossi P, Hansen AR, et al. Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. Eur J Cancer. 2019;123:138–145.
   PubMed Web of Science ®Google Scholar
• Taylor K, Loo Yau H, Chakravarthy A, et al. An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. J Immunother Cancer. 2020;8(2):e000883.
   PubMed Web of Science ®Google Scholar
• Levy BP, Giaccone G, Besse B, et al. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. Eur J Cancer. 2019;108:120–128.
   PubMed Web of Science ®Google Scholar
• Plimack ER, Stewart DJ, Issa JP. Combining epigenetic and cytotoxic therapy in the treatment of solid tumors. J Clin Oncol. 2007;25(29):4519–4521.
   PubMed Web of Science ®Google Scholar
• Ma R, Rei M, Woodhouse I, et al. Decitabine increases neoantigen and cancer testis antigen expression to enhance T cell-mediated toxicity against glioblastoma. Neuro Oncol. 2022.
   Google Scholar
• Chiappinelli KB, Strissel PL, Desrichard A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 2015;162(5):974–986.
   PubMed Web of Science ®Google Scholar
• Yu G, Wu Y, Wang W, et al. Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment. Cell Mol Immunol. 2019;16(4):401–409.
   PubMed Web of Science ®Google Scholar
• Wrangle J, Wang W, Koch A, et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget. 2013;4(11):2067–2079.
   PubMed Web of Science ®Google Scholar
• Morgensztern D, Cobo M, Ponce Aix S, et al. ABOUND.2L+: a randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). Cancer. 2018;124(24):4667–4675.
   PubMed Web of Science ®Google Scholar
• Kalff A, Khong T, Mithraprabhu S, et al. Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). Leuk Lymphoma. 2019;60(9):2143–2151.
   PubMed Web of Science ®Google Scholar
• Ruan J, Moskowitz AJ, Mehta-Shah N, et al. Multi-center phase II study of oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma (PTCL). Blood. 2020;136(Suppl. 1):33–34.
   Google Scholar
• Martin P, Bartlett NL, Chavez JC, et al. Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood. 2022;139(8):1147–1159.
   PubMed Web of Science ®Google Scholar
• Brem EA, Li H, Beaven AW, et al. SWOG 1918: a phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – aiming to improve therapy, outcomes, and validate a prospective frailty tool. J Geriatr Oncol. 2021;13(2):258–264.
   PubMed Web of Science ®Google Scholar
• Mehta-Shah N, Kahl B. Moving beyond CHO(E)P for peripheral T-cell lymphoma. Hematologist. 2021;18(5).
   Google Scholar
• Lemonnier F, Safar V, Beldi-Ferchiou A, et al. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. Blood Adv. 2021;5(2):539–548.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang S, Chen J, et al. Histone deacetylases (HDACs) guided novel therapies for T-cell lymphomas. Int J Med Sci. 2019;16(3):424–442.
   PubMed Web of Science ®Google Scholar
• Ferraris D, Duvall B, Delahanty G, et al. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. J Med Chem. 2014;57(6):2582–2588.
   PubMed Web of Science ®Google Scholar
• Neil GL, Moxley TE, Kuentzel SL, et al. Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice. Cancer Chemother Rep. 1975;59(3):459–465.
   PubMedGoogle Scholar
• Camiener GW, Smith CG. Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. Biochem Pharmacol. 1965;14(10):1405–1416.
   PubMed Web of Science ®Google Scholar
• Lavelle D, Vaitkus K, Ling Y, et al. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood. 2012;119(5):1240–1247.
   PubMed Web of Science ®Google Scholar
• DeSimone J, Heller P, Molokie RE, et al. Tetrahydrouridine, cytidine analogues, and hemoglobin F. Am J Hematol. 1985;18(3):283–288.
   PubMed Web of Science ®Google Scholar
• Molokie R, Lavelle D, Gowhari M, et al. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study. PLoS Med. 2017;14(9):e1002382.
   PubMed Web of Science ®Google Scholar
• Sohal D, Krishnamurthi S, Tohme R, et al. A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer. Am J Cancer Res. 2020;10(9):3047–3060.
   PubMed Web of Science ®Google Scholar
• Hill B, Jagadeesh D, Pohlman B, et al. A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies. Semin Hematol. 2021;58(1):35–44.
   PubMed Web of Science ®Google Scholar
• Oganesian A, Redkar S, Taverna P, et al. Preclinical data in cynomolgus (cyn) monkeys of ASTX727, a novel oral hypomethylating agent (HMA) composed of low-dose oral decitabine combined with a novel cytidine deaminase inhibitor (CDAi) E7727. Blood. 2013;122(21):2526.
   Web of Science ®Google Scholar
• Savona MR, Odenike O, Amrein PC, et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019;6(4):e194–e203.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Griffiths EA, Steensma DP, et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020;136(6):674–683.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, McCloskey J, Griffiths EA, et al. Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3 study (ASCERTAIN study) of an oral hypomethylating agent ASTX727 (cedazuridine/decitabine) compared to IV decitabine. Blood. 2019;134(Suppl. 1):846.
   PubMedGoogle Scholar
• Savona MR, McCloskey JK, Griffiths EA, et al. Clinical efficacy and safety of oral decitabine/cedazuridine in 133 patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Blood. 2020;136(Suppl. 1):37–38.
   Google Scholar
• Jabbour E, Short NJ, Montalban-Bravo G, et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017;130(13):1514–1522.
   PubMed Web of Science ®Google Scholar
• Muvarak NE, Chowdhury K, Xia L, et al. Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents – a potential therapy for cancer. Cancer Cell. 2016;30(4):637–650.
   PubMed Web of Science ®Google Scholar
• Onureg IB; 2022. Available from: https://packageinserts.bms.com/pi/pi_onureg.pdf
   Google Scholar
• Inqovi IB; 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212576s000lbl.pdf
   Google Scholar
• Ramsey HE, Oganesian A, Gorska AE, et al. Oral azacitidine and cedazuridine approximate parenteral azacitidine efficacy in murine model. Target Oncol. 2020;15(2):231–240.
   PubMed Web of Science ®Google Scholar